ESR projects

Research project

Phenotypic heterogeneity of myelodysplastic cells and influence of epigenetic therapies (WP1)

Rationale and objectives

The role of phenotypic, notably transcriptomic, heterogeneity in disease progression is not known. We will test how therapies with epidrugs (HMAs and IDH inhibitors) channel this heterogeneity.

See more

Our objectives are:

• To prospectively compare the evolution of heterogeneity (scRNA+DNA-seq) in MDS/sAML patients treated with HMAs.

• To integrate in collaboration with the Santini group transcriptomic evolution with DNA methylation.

• To retrospectively analyze the genetic and transcriptomic evolution of IDH-mutated MDS patients treated in clinical trials.

See less

Envisioned secondments

GenomeScan B.V. (The Netherlands, 2 months), University of Bergen (Norway, 2 months).

PhD programme

Université de Paris